Categories: News

Progressive Care Completes Expansion, Launches COVID-19 Rapid Testing at New Orlando Location

MIAMI, FL, Feb. 01, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – Progressive Care Inc. (OTCQB:RXMD) (“Progressive Care” or the “Company”), a personalized healthcare services and technology company, is excited to announce that its new 3,700 square foot Orlando pharmacy has now officially opened for business as a potent full-service location that is also expected to act as a growth hub for rapid results viral testing services, Covid-19 vaccinations, and 340B third-party administration contracting.

The move will allow for a dramatic expansion in services of PharmCoRx pharmacy medication therapy and medication adherence management, and Covid-19 rapid testing solution.

The new location sits just minutes from Orlando International Airport, which will facilitate ease of access for international and out-of-state travelers in need of rapid results Covid-19 testing services required prior to departure as well as the administration of Covid-19 vaccinations (when available).

“This is a jump from a small, bare-bones, fringe outpost store to a state-of-the-art, full-sized, robotics-equipped hub in one of our largest markets,” commented Alan Jay Weisberg, CEO and Chairman of Progressive Care. “The addition to our end-market footprint here promises to have a strong impact on the performance of our core pharmacy services business, as well as our testing and 340B operations with new 340B covered entities under contract. We anticipate substantial growth as we continue to ramp up our Orlando operations.”

For more information about Progressive Care, please visit the Company’s website. Connect and stay in touch with us on social media:

Progressive Care Inc.

https://progressivecareus.com

https://www.facebook.com/ProgressiveCareUS/

https://twitter.com/ProgressCareUS

PharmCoRx

https://www.pharmcorx.com/get-tested-now

https://www.facebook.com/pharmcorx/

https://twitter.com/PharmCoRx

About Progressive Care Progressive Care Inc. (OTCQB: RXMD), through its subsidiaries, is a Florida health services organization and provider of prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long-term care facilities, and health practice risk management.

Cautionary Statement Regarding Forward-Looking Statements Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company’s expectations about its future operating results, performance, and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target,” “intend” and “expect” and similar expressions, as they relate to Progressive Care Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

Public Relations Contact:
Carlos Rangel
carlosr@pharmcorx.com

Staff

Recent Posts

Rapid Dose Therapeutics Reports Fiscal Year 2024 Financial Results

Burlington, Ontario--(Newsfile Corp. - July 2, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or…

41 mins ago

Zepp Health Introduces Zepp OS 4: Redefining Wearable Intelligence by Integrating OpenAI’s GPT-4o into its Amazfit Smartwatches

Amazfit Active becomes the world's first smartwatch under €200 to fully-integrate AI. MILPITAS, Calif., July…

3 hours ago

Mission Therapeutics awarded $5.2m from The Michael J. Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325

Investment will support investigation of Mission's small molecule drug MTX325 in patients with early-stage Parkinson's…

3 hours ago

Clarivate Identifies Six Breakthrough MedTech Trends in 2024 Set to Unlock New Industry Opportunities

New report highlights challenges and opportunities in resilient MedTech industry LONDON, July 2, 2024 /PRNewswire/…

3 hours ago

Poolbeg Pharma PLC Announces Change of Registered Address

Change of Registered AddressLONDON, UK / ACCESSWIRE / July 2, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), ('Poolbeg'…

6 hours ago